Key Takeaways:
- AstraZeneca (AZN, Financial) is forecasted to have a potential upside of over 33% based on current analyst price targets and GF Value estimates.
- The stock is rated as "Outperform" by brokerage firms, indicating positive sentiment from analysts.
- Upcoming earnings on April 29, 2025, are highly anticipated by investors.
AstraZeneca (AZN) closed the latest trading session at $64.90, marking a decline of 1.35%. While this outpaced the broader S&P 500 index, which fell by 1.57%, it still reflects the stock's challenging month. Over the last 30 days, AstraZeneca's shares have plummeted by 13.42%, underperforming both the Medical sector and the S&P 500. Investors are now keenly focused on AstraZeneca's upcoming earnings release on April 29, 2025. Market projections anticipate earnings per share (EPS) of $1.11 and total revenue of $13.6 billion, signaling potential growth for the company.
Wall Street Analysts Forecast
Analysts are optimistic about AstraZeneca's future performance, providing one-year price targets that average $87.28. The low estimate stands at $67.00, while the high reaches $97.00, indicating a wide range of expectations. Current assessments imply a substantial upside of 34.49% from the current trading price of $64.90. For more detailed forecasts, refer to the AstraZeneca PLC (AZN, Financial) Forecast page.
The consensus recommendation from 12 brokerage firms places AstraZeneca with an average recommendation score of 1.8, which signifies an "Outperform" status. This rating is based on a scale from 1 to 5, where 1 represents a Strong Buy and 5 indicates a Sell, reflecting overall positive sentiment from the analyst community.
According to GuruFocus estimates, the GF Value for AstraZeneca PLC (AZN, Financial) in the next year is calculated to be $86.83. This suggests a potential upside of 33.79% from its current market price of $64.90. The GF Value employs historical trading multiples, past growth, and future performance estimates to determine the fair trading value of the stock. Further insights are available on the AstraZeneca PLC (AZN) Summary page.
